Stock Analiz

Anbio Biotechnology NNNN

Biotechnology: In Vitro & In Vivo Diagnostic Substances · IPO 2025 · data as of November 13, 2026

$3.82Market cap $550M
Open the interactive analysis →

Anbio Biotechnology (NNNN) is a healthcare company listed in the US with a market value of about $550M. In fiscal year 2025 it had revenue of $9M and net income of $6M, a net margin of 74.1%.

Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).

Key numbers: a P/E of 85.8, a 5-year average ROIC of 27%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 87% below the current price.

About Anbio Biotechnology

Anbio Biotechnology is listed in the US and classified in biotechnology: in vitro & in vivo diagnostic substances, IPO year 2025. Revenue went from $24M in 2022 to $9M in 2025, a decline of about 28.4% a year. It was profitable in 4 of the last 4 years in our data. It spends 2% of revenue on research and development.

Score: 1.4 / 5

Value0/5
Future growth1/5
Track record2/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • Profit margin improving
  • 5-year average ROIC above 12%
  • ROE above 15%
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)85.8
Forward P/E—
P/FCF—
P/S63.6
P/B18.2
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−87%

Growth and quality

Revenue growth (1 yr)5.6%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)44.8%
ROIC (5-yr avg.)27.0%
Profitable years (of last 10)4
Years paying a dividend—

Financials, last 4 years

Fiscal year2025202420232022
Revenue$9M$8M$7M$24M
Net income$6M$2M$2M$10M
Free cash flow————
EPS (diluted)$0.04$0.02$0.02$0.07
Net margin74.1%29.0%33.6%42.5%
ROIC19.1%11.6%13.2%64.2%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

What is Anbio Biotechnology’s P/E ratio?

About 85.8, based on the last twelve months of diluted earnings per share.

Is Anbio Biotechnology stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 87% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Anbio Biotechnology pay a dividend?

Not currently.

Is Anbio Biotechnology a good stock to buy?

We do not give buy or sell advice. Anbio Biotechnology scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.